Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2021 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff

WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
February 16, 2021 16:05 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021Positive Phase 3 data on topical roflumilast cream in plaque psoriasis...
February 16, 2021 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing...
February 02, 2021 20:03 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock

WESTLAKE VILLAGE, Calif,, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing...
February 01, 2021 16:09 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing...
February 01, 2021 07:30 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis

Roflumilast cream demonstrated statistically significant superiority over vehicle on primary endpoint of IGA SuccessFavorable safety and tolerability profile in this patient populationNew Drug...
January 20, 2021 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis

Phase 3 development to consist of single pivotal trialPreviously reported data demonstrated that roflumilast foam provided statistically significant improvement and a favorable safety and tolerability...
January 13, 2021 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis

Roflumilast cream potential “Best in Class” topical PDE4 inhibitorAtopic dermatitis affects approximately 19 million patients in the U.S.The Company anticipates topline data in the second half of 2022...
January 11, 2021 09:00 ET | Source: Arcutis Biotherapeutics, Inc.

Matthew Moore Joins Arcutis as Chief Business Officer

WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
December 21, 2020 09:27 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index

WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...

keyboard_arrow_left Previous Page